Related references
Note: Only part of the references are listed.Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study
Lasse Hjort Jakobsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma
Matthew J. Maurer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
The Danish National Lymphoma Registry: Coverage and Data Quality
Bente Arboe et al.
PLOS ONE (2016)
Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma
Tarec Christoffer El-Galaly et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
H. Tilly et al.
ANNALS OF ONCOLOGY (2015)
A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry
Anne O. Gang et al.
LEUKEMIA & LYMPHOMA (2015)
Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era
Chieh-Sheng Lu et al.
LEUKEMIA & LYMPHOMA (2015)
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
Laurie H. Sehn et al.
BLOOD (2015)
Evaluating Random Forests for Survival Analysis Using Prediction Error Curves
Ulla B. Mogensen et al.
Journal of Statistical Software (2015)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou et al.
BLOOD (2014)
Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry
Fredrik Ellin et al.
BLOOD (2014)
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Matthew J. Maurer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas
Raju K. Pillai et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks
Paul Blanche et al.
STATISTICS IN MEDICINE (2013)
Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era
Hiroyuki Takahashi et al.
CANCER (2012)
Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era
Marita Ziepert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
RANDOM SURVIVAL FORESTS
Hemant Ishwaran et al.
ANNALS OF APPLIED STATISTICS (2008)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
Evaluating prediction rules for t-year survivors with censored regression models
Hajime Uno et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2007)
Consistent estimation of the expected brier score in general survival models with right-censored event times
Thomas A. Gerds et al.
BIOMETRICAL JOURNAL (2006)
Dichotomizing continuous predictors in multiple regression: a bad idea
P Royston et al.
STATISTICS IN MEDICINE (2006)
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects
P Royston et al.
STATISTICS IN MEDICINE (2002)
Share Paper
